胃舒胶囊对慢性萎缩性胃炎癌前病变增殖细胞核抗原及AgNOR的影响

目的：探讨胃舒胶囊对萎缩性胃癌前病变的治疗作用及机制。方法：192例萎缩性胃炎癌前病变患者随机分为两组，治疗组（128例）给予胃舒胶囊，对照组（64例）给予胃宁冲剂冲服，疗程均为6个月。观察两组患者临床、内镜、病理疗效及治疗前后AgNOR颗粒数、增殖细胞核抗原（PCNA）表示积分值的变化。结果：治疗组临床总有效率为91．4％，胃镜有效率70．3％，对萎缩、肠上皮化生、异型增生的有效率分别为64．1％、66．4％、67．9％，并能降低其积分值。治疗组治疗前后免疫组化结果显示，胃舒胶囊也能显著降低AgNOR颗粒数、抑制PCNA的表达，与对照组比较差异有显著性意义（P＜0．01，＜0．05）。结论：胃舒胶囊对萎缩性胃炎癌前病变的临床症状、胃镜征象、病理变化有显著改善作用，其机制可能与抑制和纠正细胞的异常增殖和分化有关。

Effect of Weishu Capsule on PCNA,AgNOR of Precancerous Lesions of Chronic Atrophic Gastritis

Objective：To explore the therapeutic effect and mechanism of Weishu capsule (WSC) in treating precancerous lesions of chronic atrophic gastritis(CAG).Methods：192 cases of precancerous lesions of CAG were distributed to two groups randomly,the treated group(128 patients) was treated with WSC by taken orally and the control group (64 patients) was treated with Weining granule(WNG) orally.The treatment of course of both groups were 6 months.The clinical,gastroscopic and pathological effects and the changes in numbers of AgNOR granule and scores of PCNA expression were observed before and after treatment.Results：The total effective rate was 91.4% and the effective rate of gastroscope,atrophy,intestinal metaplasia,dysplasia in the treated group were 70.3%,64.1%,66.4%,67.9% respectively, and the respective score were lowered significantly after treatment.Immunohistochemical test showed that WSC could reduce the numbers of AgNOR granule and inhibit the expression of PCNA significantly,compared with the control group,the difference between the two groups was significant(P＜0.01，＜0.05).Conclusion：WSC could significantly improve the clinical,gastroscopic and pathological changes in the precancerous lesions of CAG.The mechanism might be related to inhibit and correct the abnormal proliferation and differentiation of cells.